Tharimmune, Inc., (Nasdaq:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced ...

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and ...

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Integrating a Different Mechanism of Action, a different Class ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...